InflaRx NV (InflaRx NV) Price-to-Operating-Cash-Flow

: (As of Today)

View and export this data going back to 2017. Start your Free Trial

As of today (2024-04-19), InflaRx NV's share price is $1.30. InflaRx NV's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.76. Hence, InflaRx NV's Price-to-Operating-Cash-Flow Ratio for today is .

The historical rank and industry rank for InflaRx NV's Price-to-Operating-Cash-Flow or its related term are showing as below:

IFRX's Price-to-Operating-Cash-Flow is not ranked ^*
in the Biotechnology industry.
Industry Median: 24.39
* Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.

InflaRx NV's Cash Flow from Operations per share for the three months ended in Dec. 2023 was $-0.20. Its Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.76.

During the past 3 years, the average Operating Cash Flow per Share Growth Rate was 23.00% per year. During the past 5 years, the average Operating Cash Flow per Share Growth Rate was 11.30% per year.

During the past 9 years, InflaRx NV's highest 3-Year average Operating Cash Flow per Share Growth Rate was 24.00% per year. The lowest was -101.70% per year. And the median was -2.95% per year.

InflaRx NV Price-to-Operating-Cash-Flow Historical Data

The historical data trend for InflaRx NV's Price-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InflaRx NV Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Price-to-Operating-Cash-Flow

InflaRx NV Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Price-to-Operating-Cash-Flow																-	-	-	-	-

Competitive Comparison

For the Biotechnology subindustry, InflaRx NV's Price-to-Operating-Cash-Flow, along with its competitors' market caps and Price-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

InflaRx NV Price-to-Operating-Cash-Flow Distribution

For the Biotechnology industry and Healthcare sector, InflaRx NV's Price-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where InflaRx NV's Price-to-Operating-Cash-Flow falls into.

InflaRx NV Price-to-Operating-Cash-Flow Calculation

InflaRx NV's Price-to-Operating-Cash-Flow ratio for today is calculated as

Price-to-Operating-Cash-Flow Ratio	=	Share Price	/	Cash Flow from Operations per share (TTM)
	=	1.30	/	-0.759
	=

InflaRx NV's Share Price of today is $1.30.
InflaRx NV's Cash Flow from Operations per share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.76.

Note: Cash Flow from Operations per share is calculated as Cash Flow from Operations divided by Shares Outstanding (Diluted Average).

It can also be calculated from the numbers for the whole company:

Price-to-Operating-Cash-Flow Ratio

Market Cap

Cash Flow from Operations

InflaRx NV Price-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of InflaRx NV's Price-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.

InflaRx NV (InflaRx NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » InflaRx NV (NAS:IFRX) » Definitions » Price-to-Operating-Cash-Flow

Comparable Companies

Traded in Other Exchanges

IF0:Germany IF0:Germany

Address

Winzerlaer Strasse 2, Jena, DEU, 07745

Website

https://www.inflarx.de

InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its lead product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.